资源描述:
《SABCSDisclosureReport12-7-2014》由会员上传分享,免费在线阅读,更多相关内容在学术论文-天天文库。
1、Program#AbstractTitleFirstnameLastnameDisclosureInformationLORELEI:APhaseIIrandomized,double-blindstudyofneoadjuvantletrozoleplustaselisib(GDC-0032)versusletrozoleplusplaceboinpostmenopausalwomenwithER-positive/HER2-Dr.BaselgahasdisclosedthathehasanOT1-1-01negat
2、ive,earlystagebreastcancerJoseBaselgaadvisoryboardmembershipfromGenentech.LORELEI:APhaseIIrandomized,double-blindstudyofneoadjuvantletrozoleplustaselisib(GDC-0032)versusletrozoleplusplaceboinpostmenopausalwomenwithER-positive/HER2-Dr.deAzambujahasnorelevantfinan
3、cialOT1-1-01negative,earlystagebreastcancerEvandrodeAzambujarelationshipstodisclose.LORELEI:APhaseIIrandomized,double-blindstudyofneoadjuvantletrozoleplustaselisib(GDC-0032)versusletrozoleplusplaceboinpostmenopausalwomenwithER-positive/HER2-Dr.Dubskyhasnorelevan
4、tfinancialOT1-1-01negative,earlystagebreastcancerPeterDubskyrelationshipstodisclose.LORELEI:APhaseIIrandomized,double-blindstudyofneoadjuvantletrozoleplustaselisib(GDC-0032)versusletrozoleplusplaceboinpostmenopausalwomenwithER-positive/HER2-Mr.Feshasnorelevantfi
5、nancialrelationshipsOT1-1-01negative,earlystagebreastcancerChristianFestodisclose.LORELEI:APhaseIIrandomized,double-blindstudyofneoadjuvantletrozoleplustaselisib(GDC-0032)versusletrozoleplusplaceboinpostmenopausalwomenwithER-positive/HER2-Ms.Fredicksonhasdisclos
6、edsheisanOT1-1-01negative,earlystagebreastcancerJillFredicksonemployeeofGenentech.Dr.GnanthasdisclosedthatheisaconsultantforAstraZeneca,Novartis,andAccelsiors.HealsodisclosedthatheisaspeakerforAmgen,LORELEI:APhaseIIrandomized,double-blindNovartis,GlaxoSmithKline
7、,AstraZeneca,Roche,studyofneoadjuvantletrozoleplustaselisibNanostringTechnologies,Eisai,andGenomic(GDC-0032)versusletrozoleplusplaceboinHealth.andthathehascontractswithSanofi-postmenopausalwomenwithER-positive/HER2-aventis,Novartis,Roche,GSK,Pfizer,andSmithOT1-1
8、-01negative,earlystagebreastcancerMichaelGnantMedical.LORELEI:APhaseIIrandomized,double-blindstudyofneoadjuvantletrozoleplustaselisib(GDC-0032)versusletrozoleplusplac